Troy A. Ignelzi - 23 May 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/ Troy Ignelzi
Issuer symbol
N/A
Transactions as of
23 May 2023
Net transactions value
-$1,927,862
Form type
4
Filing time
25 May 2023, 17:00:36 UTC
Previous filing
24 Feb 2023
Next filing
24 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $82,800 +9,000 +30% $9.20* 39,487 23 May 2023 Direct
transaction KRTX Common Stock Sale $160,207 -724 -1.8% $221.28 38,763 23 May 2023 Direct F1, F2
transaction KRTX Common Stock Sale $465,148 -2,093 -5.4% $222.24 36,670 23 May 2023 Direct F1, F3
transaction KRTX Common Stock Sale $738,602 -3,309 -9% $223.21 33,361 23 May 2023 Direct F1, F4
transaction KRTX Common Stock Sale $239,883 -1,070 -3.2% $224.19 32,291 23 May 2023 Direct F1, F5
transaction KRTX Common Stock Sale $230,144 -1,022 -3.2% $225.19 31,269 23 May 2023 Direct F1, F6
transaction KRTX Common Stock Sale $176,677 -782 -2.5% $225.93 30,487 23 May 2023 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -9,000 -8.7% $0.000000 94,726 23 May 2023 Common Stock 9,000 $9.20 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.72 to $221.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (7) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.72 to $222.71, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.72 to $223.69, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.72 to $224.71, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.73 to $225.66, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.73 to $226.26, inclusive.
F8 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.